Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV
This study has been completed.
Lisichansk Regional Tuberculosis Dispensary
Information provided by (Responsible Party):
Galyna Kutsyna, Lisichansk Regional Tuberculosis Dispensary
First received: February 2, 2010
Last updated: April 16, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||April 2015|
|Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
Efremenko YV, Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Mospan IV, Pylypchuk VS, Rowe J, Jirathitikal V, Bourinbaiar AS, Kutsyna GA. Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy. 2012 Mar;4(3):273-82. doi: 10.2217/imt.11.176.